Etid klinik pou Leukemi nan Vermont
4 etid pou Leukemi ap chèche patisipan nan sit nan Vermont.
Vil nan Vermont
Tèks ofisyèl etid la (Anglè)
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- University of Vermont, Burlington
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT06001788Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Vermont Medical Center, Burlington
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT07007312Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens
- University of Vermont Medical Center, Burlington
Ap rekriteEtid obsèvasyon
Jiska laj 30 · Tout sèks · Mizajou Jul 16, 2026 · NCT04968834Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- University of Vermont and State Agricultural College, Burlington
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou May 18, 2026 · NCT01790152Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.